Advancements in Multiple Myeloma Care: Frontline Treatment Strategies in Newly Diagnosed Multiple Myeloma : Episode 1
Key Trials in Transplant-Ineligible NDMM
Beth Faiman, PhD, CNP, discusses how to optimize treatment strategies for multiple myeloma patients by considering factors like transplant eligibility, risk stratification, and emerging clinical trial data from PERSEUS, MAIA, and CEPHEUS to guide decisions around initial therapy, maintenance approaches, and the use of novel drug combinations.
Video content above is prompted by the following:
- How are you currently approaching frontline therapy for transplant-ineligible multiple myeloma patients?
- What key factors do you consider when selecting initial treatment regimens?
- How have recent trials like PERSEUS, CASSIOPEIA, and GMMG HD7 transformed your treatment approach?
- How do you incorporate risk stratification into your treatment planning?
- How do you interpret the correlation between depth and sustained minimal residual disease negativity and patient outcomes?
- What is your approach to selecting regimens for transplant-ineligible patients?
- How do you differentiate between quadruplet and triplet regimens?
- What insights have trials like MAIA, BENEFIT, and CEPHEUS provided in guiding your treatment decisions?
- What factors influence your decision on when to transition patients to maintenance therapy?
- How do you determine the optimal maintenance regimen—dual versus triplet combinations?
- What are the key considerations for maintenance duration, particularly for high-risk versus standard-risk patients?
- How are you personalizing treatment approaches based on individual patient characteristics?
- What emerging strategies or ongoing trials are most promising for improving frontline multiple myeloma care?
- How do you anticipate treatment approaches evolving in the next few years?
Related Content
